Effects of temazepam 7.5 mg and temazepam 15 mg on sleep maintenance and sleep architecture in a model of transient insomnia
Authors:
- Milton K. ErmanMEMilton K. Erman
- Derek LoewyDLDerek Loewy
- Martin B. ScharfMSMartin B. Scharf
- 1 February 2005
- journal article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 21 (2) , 223-229
Abstract
To compare the effects of temazepam 7.5 mg and temazepam 15 mg on sleep maintenance during the last third of the night (last 160 min) and on sleep architecture throughout the night. This was a retrospective analysis of a previously reported double-blind, randomized, uncontrolled, parallel-group, multicenter study. Healthy subjects with previous but no current complaints of transient insomnia were enrolled. Transient insomnia was induced in the sleep laboratory by means of the 'first night' effect and by implementing a 2-h phase advance. The effects of both doses of temazepam on polysomnographic measures of sleep were evaluated for 1 night. The primary, prospectively-defined analysis of this study showed that 7.5-mg and 15-mg doses of temazepam had equivalent effects on latency to persistent sleep, total sleep time, and the number of sleep interruptions recorded over an 8-h period. Both doses were well tolerated. The post hoc analysis reported here compared these 2 doses for their effects on sleep maintenance and architecture. Sleep efficiency during the last third of the night was designated as the primary endpoint. The methodology for this analysis was fully defined and documented prior to re-analysis of the database for these parameters. Sixty-five subjects received temazepam 7.5 mg and 66 received temazepam 15 mg. No statistically significant differences between doses were detected for sleep efficiency or number of sleep interruptions during the last third of the night. Sleep architecture (measured over 8 h) did not differ significantly between groups. The 7.5-mg and 15-mg doses of temazepam were equally effective for maintaining sleep during the last third of the night. Continuity of sleep throughout the night, as reflected by sleep architecture, was also similar regardless of dose. In keeping with current practice guidelines, initiation of treatment with temazepam for transient insomnia should begin with the 7.5 mg dose.Keywords
This publication has 12 references indexed in Scilit:
- Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled studyEuropean Neuropsychopharmacology, 2004
- Impaired Nighttime Sleep in Healthy OldVersusYoung Adults Is Associated with Elevated Plasma Interleukin-6 and Cortisol Levels: Physiologic and Therapeutic ImplicationsThe Journal of Clinical Endocrinology & Metabolism, 2003
- Zaleplon improves sleep without producing rebound effects in outpatients with insomniaInternational Clinical Psychopharmacology, 2000
- Symptom-Based Prevalence of Sleep Disorders in an Adult Primary Care PopulationSleep and Breathing, 2000
- Benzodiazepines and Zolpidem for Chronic InsomniaJAMA, 1997
- Prevalence, burden, and treatment of insomnia in primary careAmerican Journal of Psychiatry, 1997
- Sleep Complaints Among Elderly Persons: An Epidemiologic Study of Three CommunitiesSLEEP, 1995
- Insomnia in Generalized Anxiety Disorder: Polysomnographic, Psychometric and Clinical Investigations before, during and after Therapy with a Long- versus a Short-Half-Life Benzodiazepine (Quazepam versus Triazolam)Neuropsychobiology, 1994
- Electoencephalographic Sleep in Recently Remitted, Elderly Depressed Patients in Double-Blind Placebo-Maintenance TherapyNeuropsychopharmacology, 1993
- Sleep and Psychiatric DisordersArchives of General Psychiatry, 1992